SARS CoV 2 News and Research

RSS

SARS-CoV-2 activates NLRP3 inflammasome

Researchers assessed the role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the NLR family pyrin domain containing 3 (NLRP3) inflammasome activation.

7 Nov 2022

Phylodynamic analysis of the monkeypox virus genome suggests low genetic variation and evolutionary rates

Researchers explored the genetic variability among the monkeypox virus genomes of Clade IIb lineage B.1 using a phylodynamic and genetic survey to confirm the epidemic cluster in the clade and understand the evolution of the virus.

7 Nov 2022

Multinational consensus to end COVID-19 pandemic

A new study recommended specific actions to end the coronavirus disease 2019 (COVID-19) pandemic.

7 Nov 2022

Evaluating dual direct-acting antivirals against persistent COVID-19

Researchers assessed the efficiency of dual direct-acting antivirals in treating persistent coronavirus disease 2019 (COVID-19).

7 Nov 2022

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest SARS-CoV-2 antigens for the newly designated Omicron BA.5 variant.

From The Native Antigen Company 7 Nov 2022

Does the time of day patients receive their COVID-19 vaccinations influence their clinical benefit?

Researchers investigated whether the time of day at which COVID-19 patients receive their SARS-CoV-2 vaccinations influences the vaccine effectiveness.

7 Nov 2022

Pregnant patients with SARS-CoV-2 infection early in pregnancy and with active infection exhibit an altered vaginal and oral microbiota that is passed on to infants

The study findings showed that COVID-19 during pregnancy, especially in the first and second pregnancy trimesters, was associated with long-term microbiome alterations among expecting women compromising the initial microbiome of their infants.

7 Nov 2022

Thrombocytopenia may increase the risk of preeclampsia in pregnant women with COVID-19

A new study describes that COVID-19 may increase the risk of preeclampsia in pregnant women with low blood platelet count (thrombocytopenia).

7 Nov 2022

Study suggests anti-PF4 antibodies may play a role in the severe multiorgan disease manifestations of COVID-19

Researchers investigated the association between the increased levels of anti-platelet factor 4 antibodies and the clinical complications of COVID-19.

7 Nov 2022

Study shows likely SARS-CoV-2 transmission between different rooms of a quarantine hotel

The results of this study, published in the Emerging Infectious Diseases journal, underline the enhanced transmissibility of the Omicron variants of the virus, which takes advantage of small airstreams to jump to new hosts. "Our findings emphasize the importance of ventilation and integrity of building structure in quarantine facilities."

6 Nov 2022

Study finds no evidence of major SARS-CoV-2 spread among wild rodents

A new study published in the Emerging Infectious Diseases journal conducted a large-scale serologic survey of SARS-CoV-2 in multiple rodent species to determine the reverse transmission of SARS-Cov-2 and its establishment in wild rodents across different settings.

6 Nov 2022

Influenza hospitalizations at highest level in ten years, predicting a severe U.S. flu season

Influenza infection and hospitalization rates continue to increase at an alarmingly fast and early rate this year.

6 Nov 2022

Moderna's COVID-19 vaccine safe and effective in children 6 months to 5 years of age

Moderna's COVID-19 vaccine is safe and effective in children 6 months to 5 years of age, a clinical trial co-led by Vanderbilt University Medical Center vaccine expert C. Buddy Creech, MD, MPH, has found.

4 Nov 2022

Exploring BNT162b2 vaccine effectiveness against COVID-19 among pediatric and adolescent population of Qatar

Researchers evaluated Pfizer-BioNTech’s BNT162b2 messenger ribonucleic acid (mRNA) vaccine effectiveness (VE) against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infections among the pediatric and adolescent population of Qatar.

4 Nov 2022

SARS-CoV-2 Omicron's newest subvariant BQ.1.1 shows extraordinary immune evasion potential against vaccine sera

In a new study, researchers pursued immunological evidence of why BQ.1.1 prevalence swiftly increased in areas where Omicron BA.5 was dominant in the United States (US).

4 Nov 2022

What were the SARS-CoV-2 seroprevalence estimates for industrial livestock operation workers in the USA for 2021-2022?

In a new study, researchers measured SARS-CoV-2 seroprevalence in industrial livestock operation workers of North Carolina, United States, between February 2021 and July 2022.

4 Nov 2022

Persistent COVID-19 symptoms among South Africans infected during SARS-CoV-2 Beta, Delta and Omicron variant waves

Researchers longitudinally followed up hospitalized (H) and non-hospitalized (NH) COVID-19 patients for six months after laboratory-confirmed SARS-CoV-2 infections to identify factors that increase the risk of post-COVID-19 condition development in the South African population.

4 Nov 2022

Efficacy of booster messenger ribonucleic acid COVID-19 vaccinations against SARS-CoV-2 Omicron variant severity

Researchers estimated the effectiveness of monovalent messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) infection severity outcomes among adults.

4 Nov 2022

Study evaluates BA.5-bivalent booster against new Omicron sublineages

In a new study, researchers evaluated the efficacy of four doses of parental messenger ribonucleic acid (mRNA) vaccine and a BA.5-bivalent booster against recently emerged Omicron sublineages. Additionally, they determined whether prior infection improved the effect of a booster vaccination.

4 Nov 2022

Novel monoclonal antibodies NA8 and NE12 can neutralize most SARS-CoV-2 variants and Omicron subvariants

Researchers generated and characterized two monoclonal antibodies (NA8 and NE12) that target the receptor binding domain of the SARS-CoV-2 spike protein, and exhibit neutralizing activity against major SARS-CoV-2 variants of concern.

3 Nov 2022

SARS CoV 2 News and Research

SARS-CoV-2 activates NLRP3 inflammasome

Phylodynamic analysis of the monkeypox virus genome suggests low genetic variation and evolutionary rates

Multinational consensus to end COVID-19 pandemic

Evaluating dual direct-acting antivirals against persistent COVID-19

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

Does the time of day patients receive their COVID-19 vaccinations influence their clinical benefit?

Pregnant patients with SARS-CoV-2 infection early in pregnancy and with active infection exhibit an altered vaginal and oral microbiota that is passed on to infants

Thrombocytopenia may increase the risk of preeclampsia in pregnant women with COVID-19

Study suggests anti-PF4 antibodies may play a role in the severe multiorgan disease manifestations of COVID-19

Study shows likely SARS-CoV-2 transmission between different rooms of a quarantine hotel

Study finds no evidence of major SARS-CoV-2 spread among wild rodents

Influenza hospitalizations at highest level in ten years, predicting a severe U.S. flu season

Moderna's COVID-19 vaccine safe and effective in children 6 months to 5 years of age

Exploring BNT162b2 vaccine effectiveness against COVID-19 among pediatric and adolescent population of Qatar

SARS-CoV-2 Omicron's newest subvariant BQ.1.1 shows extraordinary immune evasion potential against vaccine sera

What were the SARS-CoV-2 seroprevalence estimates for industrial livestock operation workers in the USA for 2021-2022?

Persistent COVID-19 symptoms among South Africans infected during SARS-CoV-2 Beta, Delta and Omicron variant waves

Efficacy of booster messenger ribonucleic acid COVID-19 vaccinations against SARS-CoV-2 Omicron variant severity

Study evaluates BA.5-bivalent booster against new Omicron sublineages

Novel monoclonal antibodies NA8 and NE12 can neutralize most SARS-CoV-2 variants and Omicron subvariants

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News